In a recent interview with HCPLive, Jayme Heim, MSN, a Family Nurse Practitioner at West Michigan Dermatology, discussed the latest developments in dermatology, specifically focusing on atopic dermatitis and psoriasis. Heim highlighted the significance of Arcutis Biotherapeutics, Inc.’s supplemental New Drug Application (sNDA) for roflumilast cream 0.15% in the treatment of atopic dermatitis. She commended the introduction of new medications for atopic dermatitis, stating that it would greatly benefit patients who have been limited in their treatment options.
Heim emphasized the lack of available care options for conditions like atopic dermatitis, revealing that insurance companies often fail to understand the importance of these medications. With the introduction of roflumilast cream 0.15%, patients can experience improvements in their quality of life, sleep patterns, and daily functioning.
Contrary to popular belief, Heim addressed the misconception that atopic dermatitis is seen as a less impactful condition compared to others. She explained that the National Psoriasis Foundation played a critical role in raising awareness about psoriasis, while atopic dermatitis remained somewhat neglected. She stressed that these conditions are not merely superficial, but rather true physical conditions that can negatively affect patients’ psychological well-being.
Moving on to psoriasis, Heim discussed the significant results seen in patients who switched from tumor necrosis factor-alpha inhibition (TNF-α) to interleukin-17 inhibition through brodalumab. She emphasized the importance of adequately treating psoriasis, considering the high rates of depression and suicide among patients with untreated or inadequately treated psoriasis. Despite the effectiveness of brodalumab, Heim noted that many healthcare providers are hesitant to have conversations about transitioning to this medication, resulting in patients not receiving the care they need.
Overall, Heim’s insights shed light on the advancements in dermatology and the positive impact they can have on patients’ lives. With new medications and proper treatment options, individuals with atopic dermatitis and psoriasis can experience improved physical and psychological well-being.
Sources:
– Arcutis Submits Roflumilast Cream 0.15% Supplemental New Drug Application to the FDA for the Treatment of Atopic Dermatitis in Adults and Children Ages 6 Years and Older
– Andersch-Björkman et al. Effects of brodalumab on psoriasis and depressive symptoms in patients with insufficient response to TNF-α inhibitors. J Dermatol. 2023; 00: 1–14.
